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Immunotherapies have evolved into a collection of tools used clinically in the treatment 
of several pathologies. Staphylococcal enterotoxin G and I are potent T cell activators 
that drive multifaceted immune responses and have been implicated in antitumor 
responses. The addition of SEG and SEI as useful immunotherapies could be 
underappreciated as mice do not respond as humans would to superantigen stimulation. 
HLA-DQ8 mice with established B16-F10 tumors receiving 50µg each SEG and SEI 6 
and 9 days post tumor implant resulted in 80% progression free survival >300 days. In 
comparison, allogeneic C57BL/6 mice did not benefit from SEG/SEI therapy. 
Remarkably, 100% of HLA-DQ8 mice survived rechallenge with 2.5x105 live B16-F10 
cells >200 days post implant. In addition, SEG/SEI boosted an irradiated cell vaccine 
response against LLC in HLA-DQ8 mice resulting in 100% protection. However, 
SEG/SEI did not provide the same benefit against established Lewis lung carcinoma. The 
data presented herein demonstrate SEG and SEI elicit antitumor responses against 








Staphylococcal enterotoxins (SE) G and I are powerful immunostimulatory 
proteins produced by Staphylococcus aureus. In 1998, SEG and SEI were 
characterized from different enterotoxigenic strains of S. aureus and were found 
to have superantigenic properties comparable to classical enterotoxins, like SEA 
and SEB [1]. Further investigation identified several other toxins in proximity to 
SEG and SEI within the enterotoxin gene cluster (egc) of S. aureus’ pathogenicity 
island 3 (SaPI3) [2,3]. The crystal structures, bound to major histocompatibility 
complex (MHC), have also been elucidated for both SEG and SEI [4,5]. Several 
enterotoxins identified in the gene cluster have been shown to activate large 
numbers of T cells and are classified as superantigens [6-9]. Superantigens are 
molecules present in nearly all aspects of cellular biology; bacteria make 
superantigens, viruses, found endogenously in animals and suggested in plants. 
Superantigens are classified as molecules that elicit polyclonal cell activation in a 
large percentage of the cell population [10]. Superantigens were originally 
classified as only activating large number of T cells with B cell superantigens 
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documented later [11]. These non-glycosylated proteins interact outside of typical 
antigen processing and presentation pathways. In general, antigens are broken 
down proteins presented as small, ~10 amino acid, peptide lengths which are 
eloquently loaded onto the cell surface; taking place in 1 out of every 10,000 cells 
[12]. Superantigens can bypass cellular processing to directly bind to the cell 
surface, in turn activating >20% of cells leading to massive activation and 
cytokine release. Dysregulation as a result of SE activation can lead to a lethal 
cytokine storm. Enterotoxins can provoke emesis when ingested by humans and 
monkeys, often as a result of bacterial contamination of food and/or water. Mice 
nor rats have emetic responses to enterotoxins likely due to a lack of specific 
neurological architecture [13], yet still respond to enterotoxins with typical T cell 
activation and cytokine release. 
 
Superantigens isolated from Streptococcus and Staphylococcus species have been 
extensively characterized [14-17], in addition to some viral superantigens (18). 
Yersinia pseudotuberculosis mitogen (YPM) is the only identified superantigen 
from Gram negative bacteria [19], suggesting superantigens are not advantageous 
for gram negative bacteria and are either genetically repressed or have been lost 
over time. Lipopolysaccharide (LPS) from gram negative bacteria has been shown 
to dramatically enhance the effects of superantigen stimulation [14]. Enterotoxins 
can activate T cells by binding to the variable beta region on the t cell receptror 
(TCR) and MHC. Superantigens can be categorized into groups based on MHC 
interactions that: (1) bind the TCR and MHC α-chain (SEB & SEG); (2) bind 
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TCR and MHC β-chain (SEI); or (3) crosslink MHC by binding to the α-chain 
and β-chain (SEA) [14, 20, 21, 28-34]. There is controversial evidence to support 
some superantigens can also bind with MHC Class I molecules, but this 
interaction has not been completely characterized [22]. SE specificity towards Vβ 
segments of the TCR have also been extensively characterized [23- 25]. 
Superantigen dissociation rates where SEA has been shown to stay at the cell 
surface longer than SEB [26,27]. Endogenously expresses superantigens in mice 
have been shown to selectively eliminate T cells based on V beta specificity; and 
like many superantigens, endogenously synthesized superantigens are thought to 
be derived from viral DNA [28].  
 
T cells and Cancer 
Lymphocytes, immune cells slightly larger than a red blood cell (RBC), have once 
again become major players in the current landscape of cancer therapy. There are 
two general types of lymphocytes in humans and mice, B and T lymphocytes, or 
B and T cells. SEG and SEI activate T cells through the help of MHC on antigen 
presenting cells (APCs), like B cells. In combination, T cells work synergistically 
with APCs and thus responsible for the pathology associated with superanitgens 
[29-35]. Historically B and T cells were classified based on the site of maturation 
and development. Nearly all lymphocytes originate from the bone marrow. Cells 
that migrate and later mature in the bone marrow are designated B cells; whereas 
cells migrating through the thymus for maturation are called T cells. Ironically, B 
cells were originally identified in the bursa of Fabricius, a lymphoid structure in 
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birds that atrophies after 6 months of age, not the bone marrow, a rare 
happenstance with immunological nomenclature. B cells from birds are similar to 
mammalian B cells yet are derived from entirely different structures, the bursa 
and bone marrow respectively [32].  
 
The immune system is the collection of these cells, and many more, contributing 
to a delicate balance to recognize self vs non-self. Immune cells that detect 
abnormalities and homeostatic imbalance activate to purge anything deemed 
foreign. T cells, many expressing either CD4+ and CD8+, are responsible for 
surveying the host environment and eliminate cells that appear abnormal, either 
malignant or not. The inability for the immune system to recognize abnormal cells 
is a well-accepted mechanism to describe metastatic disease, like cancer. T cell 
mediated immunity in response to cancerous, abnormal cells deploy a mix of 
secreted proteins, like granzymes, perforin, interferon gamma (IFNy), and cell to 
cell contact killing [59-62]. Countless therapies have attempt to utilize T cells 
against cancer including the more recent advent of chimeric antigen receptor 
(CAR) T cells directed specifically at antigens on tumors [62]. These cells are 
then infused back into the patient through adoptive transfer. Even coupled with 
advancements in T cell therapy delivery [61], the reliability to which these 






Murine Models of Cancer 
The B16 melanoma cell line originated from a spontaneous melanoma in 
C57BL/6J mice. The cell line was later manipulated by injecting cells 
intravenously into mice, sacrificing the mice 3 weeks later to harvest lungs and 
isolate lung metastases [115]. The pulmonary metastases were made into single 
cell suspensions, grown in vitro and reinjected into C57BL/6 mice. B16-F1 cells 
underwent the aforementioned process 1 time whereas B16-F10 cells where 
subject to 10 passages from mouse to culture dish [114-118]. B16-F10 cells where 
used for this study due to the highly metastatic potential of these cells compared 
to similar models.  
 
Lewis lung carcinoma (LLC) cells were originally derived from a spontaneous 
arising tumor from C57BL/6 mice [119, 120]. LLC has been found to be a 
consistent, reproducible model to study non-small cell lung cancer (NSCLC) in 
mice and has been used in several preclinical research leading to approved 
therapies in humans. LLC and B16 cells are both epithelial in appearance, 
however, LLC cells grow loosely adherent to the flask whereas B16 cells strictly 
adhere. Of note, both cell lines will form large tumors which will overtake the 
omental tissue when injected intraperitoneally. LLC cells have also been observed 
to invade the mesentery as well as omental tissue (laboratory observation). The 
omental tissue in mice differs to humans in that it does not extend downward over 
the intestines. Murine omental tissue is also smaller, connected to the stomach, 
pancreas and spleen. Harvesting the omentum should be done using the method 
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described in Kahn et al. which uses a flotation technique to isolate the omental 
tissue from the surrounding organs [102]. The omentum has been shown to 
contain immune aggregates, sometimes referred to as milky spots because of their 
fatty white appearance, along with fat and blood vessels. Preferential attachment 
to the omentum has been suggested to result from several factors: the available 
blood supply and VCAM expression on mesothelial cells which also secreted 
VEGF-A [104].  
 
Historical Perspective: Immunotherapies 
The treatment of malignant disease has been meticulously documented throughout 
many generations of human evolution where early recordings of the disease in the 
Edwin Smith Papyrus date back to around 3000 BC [51-58].  The many 
documented accounts throughout history illustrate an evolution of human 
responses tied to an emotional and physical relationship with disease. Often 
described are crude, yet sophisticated, techniques of excising disease, sometimes 
tumors, through surgical techniques; many of which, though refined, are still 
recognizable in practice. Swiss physician Paracelsus is often credited for laying 
the foundation for chemotherapy and regarded as a founding father of toxicology. 
Paracelsus’ introduction to his self-described “poisonous compounds”, including 
mercury, zinc, lead and more as treatments for internal disease eventually lead to 
his death in 1541 [55].   
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The ensuing centuries led to more and more observations that seemingly 
advanced understanding of malignant disease. Physicians and scientists would 
continue to make and mold hypothesis to endless, often reckless means. Jean 
Astruc, an early 1700s French physician, carried out experiments to identify 
differences in the acidity of cooked meat in relation to bile, by taste [57]. He 
noted no difference in taste between cooked beef or cancerous breast. For years, 
the battle between cancer and scientist will continue to claim countless lives and 
shape the course of human history. German Emperor Frederick III, ruling for 99 
days until his death in 1888 from laryngeal cancer was examined by several 
physicians, including Rudolf Virchow, colloquially referred to as “the pope of 
medicine” [55]. Virchow’s career, highlighted in numerous publications, which 
are not completely referenced here, include; linking cancer to the outgrowth of 
specific cells, specifically differentiating between splenic, myeloid appearance, 
and lymphatic, lymphocytic appearance, cells. Virchow is also one of several 
scientists credited in discovering leukemia, what he called leukämie [57]. 
Virchow, who eventually died of a broken leg sustained while jumping from a 
moving streetcar at age 80, was a staunch opponent to germ theory and was 
skeptical of the experiments demonstrating bacteria as a causative agent of 
disease[58].  
 
Spontaneous remission of an inoperable neck sarcoma was observed by William 
Coley who later injected patients with preparations of bacteria and bacterial 
byproducts, known as “Coley’s Toxins” [63]. His and others attempts at 
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controlling various malignancies stem from clinical observations in spontaneous 
regression of the diseases. Specifically, Coley administered Streptococcus 
isolations he procured from other patients, grown in culture, and administered to 
patients at the site of diseases in order to elicit erysipelas [64-66]. It was noted 
that the heat, or inflammation, generated was crucial in a durable response. These 
pioneering, yet rudimentary in practice, paved the way for years of research into 
toxin-based therapies. Coley, often credited as the Father of immunotherapy, the 
treatment of 30 (of 270) cases were outlined in a review published posthumously 
by his daughter, Helen Coley Nauts [64].  Attempts to refine as isolate 
compounds from these preparations is outside the scope of this discussion, suffice 
to say that many are still working on it at the time of writing this. One such 
component that has been shown to contribute towards controlling malignant cell 
outgrowth are superantigens [71-77]. 
 
The 1990s brought the race for tumor associated antigens (TAAs). In 1988, 
Steven Rosenberg, now current Head of the National Institute of Health’s Tumor 
Immunology Section, and colleagues isolated tumor infiltrating lymphocytes 
(TILs), expanded them in vivo via IL-2, and infused them back into the patients 
[book]. Although this did not yield substantial responses, this was the first time T-
cells were specifically used as a therapy, a paradigm shift in the way we think 
about treating cancer.  Several labs over the next 30 years have been perfecting 
the use of T-cells as therapies [60, 74]. 
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Enterotoxins and Cancer 
Over the past decade, numerous immunotherapies have provided some respite for 
patients with a variety of cancer types [67]. Though still in its infancy, 
immunotherapy has yet to live up to expectations in providing consistent 
progression free survival, let alone complete regression. The first publication of 
monoclonal antibody use in clinical trials in 2002 targeted CTLA4 expressed on T 
cells [152]. It took until 2011 for Ipilimumab (Yervoy® under Bristol-Myers 
Squib) to be approved for the treatment of melanoma in the United Sates[153]. 
Cancer vaccine strategies have been largely unsuccessful with one approved 
therapy, Sipuleucel-T (Provenge® under Dendreon) in 2010, for hormone-
refractory prostate cancer [154]. Although one can hypothesize revisiting this as a 
future waste of time, results have not been released (NCT01832870) from 9 
patients receiving Sipuleucel-T and Ipilimumab. Nonetheless, combinations of 
different immunotherapies, specifically CTLA-4 and PD-1 antagonists, have 
proven beneficial when used together [154].  
 
Several, largely unsuccessful, therapies have attempted to use SEs in to treat 
various cancers. Several of these studies were hindered by the presence of 
neutralizing antibodies to classical superantigens found in >80% of sampled 
human sera [68-70]. For decades, China has used Gaojusheng, an SEC based 
therapy, for the treatment of cancer [67]. Exciting work by Dr. David Terman, 
and others, have demonstrated the therapeutic efficacy in using superantigens for 
the enterotoxin gene cluster as in the treatment of pleural effusion in patients with 
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non-small cell lung cancer (NSCLC) [71]. In addition to neutralizing antibodies, 
SE therapy has been hindered by toxicity associated with increased 
proinflammatory mediators, like TNFα [21, 68-70]. Reducing adverse toxicity 
associated with SEs has included using monoclonal antibodies against CTLA-4 
[77, 151], adjusting dosages and time administered, or  adding compounds such as 
Δ9Tetrahydrocannabinol [76]. Kominsky et al. used SEA and SEB in the 
treatment of B16 melanoma and produced long term survival in C57BL/6 mice 
suggested an IFNγ mediated response that requires both CD4+ and CD8+ T cells 
[78]. 
 
The remainder of this document outline a series of experiments I performed using 
SEG and SEI in the treatment of B16 melanoma and Lewis lung carcinoma. By 
no means are these experiments comprehensive to understanding the immune 
responses elicited by SEG and SEI nor is the precise mechanism that underlies the 
phenomena presented herein. In that context, the following chapter outlines 
methods and information required, including tips and tricks observed along the 
way, for someone repeat these experiments. The results demonstrate a clear 












All research performed, including animal and tissue collection, was conducted in 
accordance with the Animal Welfare Act and with the approval of the University 
of North Dakota’s Institutional Animal Care and Usage Committee (IACUC).  
 
Mice 
Mice were bred and maintained in pathogen-free conditions within the Center for 
Biological Research at the University of North Dakota. A laboratory inbred 
colony of C57BL/6 mice and human leukocyte antigen (HLA) transgenic mice 
were used for experiments. Transgenic mice include: HLA-DQ8 
(DQA*0301/DQB*0302), originally a gift from Dr. Chella David (Mayo Clinic, 
Rochester, MN) and HLA-DR3 (DRA*0301/DRB*0301), gifted from Dr. Malak 
Kotb (University of North Dakota, Grand Forks, ND). The generation of these 
mice were described previously [84-86]. Similar to DR3 mice, DQ8 mice were 
generated on H2b haplotype mice lacking H2A (20) and inherent H2E expression, 
thus making them devoid of murine class II. Specific gene insert was confirmed 
via polymerase chain reaction (PCR) and subsequent protein expression was 
confirmed via flow cytometry using anti-DR (Clone Tu39, 
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BioLegend) and anti-DQ (Clone SK10, eBioscience) for HLA-DR3 and HLA-
DQ8 confirmation, respectively Table 1. 
 
Enterotoxins 
Purified, recombinant SEG and SEI were obtained from Aldeveron (Fargo, ND). 
SEA, SEB and SEI were obtained from Toxin Technology (Sarasota, FL). All 
reagents were kept at 4°C or -20°C and subject to only 1 freeze-thaw cycle. The 
sequences used for SEG SEI manufacturing were originally elucidated by Munson 







The protein sequence for SEG: 
MQPDPKLDEL_NKVSDYKNNKGTMGNVM NLYTSPPVEGRGVINSR 
QFLSHD LIFPIEYKSY NEVKTELENT ELANNYKDKK 81 VDIFGVPYFY 
TCIIPKSEPD INQNFGGCCM YGGLTFNSSE 121 NERDKLITVQ 
VTIDNRQSLG FTITTNKNMV TIQELDYKAR 161 HWLTKEKKLY 
EFDGSAFESG YIKFTEKNNT SFWFDLFPKK 201 ELVPFVPYKF 






Antibody Clone Company 
HLA-DQ SK10 Invitrogen 
HLA-DR,DP,DQ Tü39 BioLegend 
H-2Kb AF6-88.5 BioLegend 
I-A/I-E M5/114.15.2 BioLegend 
CD3 17A2 TONBO Biosciences 
CD4 RM4-5 BioLegend 
CD8 53-6.7 TONBO Biosciences 
CXCR3 CXCR3-173 BioLegend 
CTLA-4 UC10-4F10-11 TONBO Biosciences 
PD-1 J43.1 TONBO Biosciences 
TLR2 T2.5 BioLegend 
TLR4 SA15-21 BioLegend 
CD44 IM7 BioLegend 
CD62L MEL-14 BioLegend 
KLRG1 2F1 TONBO Biosciences 
CD25 PC61 TONBO Biosciences 
FOXP3 MF23 TONBO Biosciences 
CD103 2E7 BioLegend 
CD39 Duha59 BioLegend 
T-bet 4B10 BioLegend 
IFNγ XMG1.2 BioLegend 
Perforin S16009A BioLegend 
Granzyme B QA16A02 BioLegend 
Proliferation Dye  eBioscience 
CD16/32 93 BioLegend 
Annexin V  BioLegend 
Propidium Iodide  TONBO Biosciences 
Live/Dead  TONBO Biosciences 
 






Tumor Cell Lines 
B16-F10 (CRL-6475TM) murine melanoma cells and Lewis lung carcinoma (LLC) 
(CRL-6475TM) were obtained from American Type Culture Collection (ATCC) 
and maintained according to manufacturer recommendations in complete 
Dulbecco’s Modified Eagle’s Medium ((DMEM) Gibco) containing 10% heat 
inactivated fetal bovine serum (FBS) (Atlanta Biologicals), 50 IU/ml Penicillin 
and 50 µg/ml Streptomycin (MP Biologicals), and HEPES. Cells were maintained 
humid at 37°C with 5% CO2. Frozen 1 ml aliquot stocks were made by freezing 
~1x106 cells in complete DMEM supplemented with 50% vol/vol sterile dimethyl 
sulfoxide (DMSO). Cells were maintained in liquid nitrogen vapor phase.  
 
Of note, tissue culture flasks and other plastics used for cellular assays remained 
consistent throughout these experiments (CytoOne and Falcon). It has been 
demonstrated that different surfaces of tissue culture plastics can alter phenotypes 
of adherent cells [92, 93]. In addition, breast implants with specific textured 
surfaces were found to increase the risk of breast cancer in 82% of patients 
receiving the implant [94, 95]. The World Health Organization (WHO) 
provisionally defined the cancer in 2016 as breast implant-associated anaplastic 





Primary Cell Isolation 
Peritoneal lavage cells were isolated by sacrificing mice, injecting 5 ml HBSS 
(Gibco) into the peritoneal cavity, massaging for 10 seconds and collecting 4 ml 
of fluid. It is important to take note of injection as not to perforate or injection 
into the intestines. Cell yield will vary substantially without consistency in 
technique but will average ~1 million total cells. ACK lysis was used as needed 
while maintaining consistency. Cells were filtered through a 70 µm cell strainer 
before counting and use.  
 
Splenocytes were isolated by passing spleens through a 70 µm cell strainer 
(Falcon) with bottom plunger of 5ml or 10ml syringe. Cells were washed with 
DMEM, ACK lysed, washed and strained again before counting. Cell yield will 
depend but should average 50-100 million total cells in naïve mice.    
Inguinal lymph nodes were isolated and placed in 1ml HBSS. Nodes should sink 
when removed without major fat contamination. Both lymph nodes were mashed 
through a 70 µm cell strainer (Falcon) with bottom plunger of 5ml or 10ml 
syringe. Cells were washed with DMEM and strained again before counting. Cell 
yield is varied but average 0.5-1 million total cells per lymph node in naïve mice.    
 
Omental tissue was isolated and washed by transferring through several wells 
containing HBSS. The tissue was placed in 1 ml media in 24 well plates and cells 




Tumors were implanted intraperitoneally resulting in solid tumors at the omentum 
ultimately leading to death of the animal. 
 
Prior to implant, cells were grown in T75 tissue culture flasks and harvested for 
use at < 80% confluency. Cells were rinsed with HBSS prior to addition of trypsin 
w/EDTA (Gibco) for ~5 minutes. cDMEM was used to neutralize trypsin and 
cells were washed 2 times with HBSS. Cells were resuspended at 1x105 or 
2.5x106 cells/ml in HBSS w/ca+mg+. The stock was aliquoted into .5ml tubes for 
individual dosages to insure consistent tumor burden among mice.  
 
Of note, LLC cells typically present as a mix of suspension and adherent cells. 
For these studies, only the adherent cells were used for implant. This should not 
affect overall results as this technique was deployed in vitro and mixed 
populations continued throughout each subculture.  
 
Just before injection, after cell aspiration, wipe the needle with 70% ethanol to 









Mice were injected with 1 x 106 irradiated (15,000 rads) B16-F10 melanoma cells 
IP in 100µl HBSS on day -13. Mice received 100µl injections IP of SEG (50µg) + 
SEI (50µg) on days -7 and -3. Mice were challenged day 0 as described above. 
Mice were continuously evaluated and sacrificed when moribund.  
 
Flow Cytometry 
Cell Staining  
Cells were washed with HBSS, stained with Ghost Dye for viability (TONBO), 
FC blocked and stained for extracellular antigens via standard protocols. Cells 
were fixed and permeabilized using Foxp3 staining buffer kit (TONBO) for 
intracellular cytokine and transcription factor analysis. See Table 1 for list of 
antibodies used in this manuscript. Fluorescence minus one (FMO) and single 
stained controls were used for gating and compensation. Gating strategies are 
indicated within each experiment. In general, doublets and cell debris were 
excluded with only Ghost Dye negative cells being used for analysis. Samples 
were analyzed using a BD LSRII or Symphony A3 flow cytometer in the North 
Dakota Flow Cytometry and Cell Sorting (ND FCCS) Core. Data was analyzed 






T cell proliferation was evaluated using carboxyfluorescein succinimidyl 
ester (CFSE) (Life Technologies) or Cell Proliferation Dye eFluor 450 
(eBiosciences) dye. In short, splenocytes were stained with proliferation dye as 
described previously (25). After which, 2x105 cells/well were seeded in 96-well 
round-bottom tissue culture plates (Becton Dickinson) in cDMEM and stimulated 
with Concanavalin A (1µg/ml) (Sigma Aldrich) or indicated superantigens for 72 
hrs (37°C, 5% CO2 and humidity) in 200µl total volume. After 3 days, cells were 
processed for flow cytometry. 
 
Cytotoxicity Assay 
Cytotoxicity was measured by annexin V and propidium iodide (PI) (TONBO) 
staining. Briefly, B16-F10 cells were seeded 2 hours prior to coculture with 
lymphocytes at indicated ratios. CD4 and CD8 cells were isolated from C57BL/6 
and HLA-DQ8 splenocytes using EasySep TM CD4 and CD8 negative selection 
kits (STEMCELL Technologies) in accordance with manufacturer specifications. 
All cells were counted using a hemocytometer, cell viability was determined via 
trypan blue exclusion (>90% viabke) and purity was assessed via flow cytometry. 
Cells were cocultured for 4 hours (37°C, 5% CO2 and humidity) and stained with 
annexin V and PI using BioLegend’s annexin V binding buffer according to 
manufactures recommendations and analyzed immediately via flow cytometry. 




















Figure 1 . Gating strategy for flow cytometry-based cytotoxicity assays. 
T cells were cocultured with B16-F10 cells in 96 well flat bottom plates. Specific T 
cell responses and B16 responses can be distinguished based on separation via FSC 
vs SSC. Cytotoxicity was measured on B16 cells for annexin V and propidium iodide 
staining.  
  
B16 Cells T cells 
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Cytokines and Chemokines 
Blood was collected from mice in EDTA tubes via submandibular venipuncture. 
Plasma cytokine and chemokine concentrations were measured using 
BioLegend’s LEGENDplex™ kits according to manufacturer recommendations. 
Samples were processed via flow cytometry.  
 
Peripheral Blood Smear and Cytospin Staining 
Blood smears were made from blood collected in ethylenediaminetetraacetic acid 
(EDTA). Body fluids and single cell suspensions were resuspend in cDMEM or 
HBSS w/10% serum to maintain cell integrity. Cytospins were spun for 3 mins at 
80 x g. Smears and cytospins were stained with Hema 3Ô Wright-Geimsa 
(Fischer Scientific). Several references provide reference valves for common 
laboratory mice (122). Several common morphologies exist between human and 
murine immune cells and therefore human morphological references can provide 
guidance.  
 
Thymidine Incorporation Assay 
C57BL/6 and HLA-DQ8 splenocytes (2x105 cells/well) were seeded in 96-well 
round-bottom tissue culture plates (Becton Dickinson) in complete RPMI. 
Splenocytes were cultured 72 hrs (37°C, 5% CO2 and humidity) in 200µl total 
volume with medium alone, various concentrations of SEA, SEB, SEG, and SEI 
(0.001–1000 ng/ml) and with Concanavalin A (1.25µg/ml) (Sigma Aldrich). At 
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68 hrs incubation, cells were pulsed with 1 µCi/well [3H] thymidine (Perkin 
Elmer); radioactivity was measured 4 hours later as described previously [98].  
 
Statistical Analysis 
One-way analysis of variance with Bonferroni’s posttest and student’s t test were 
performed where indicated. Kaplan Meier curves and Mantel-Cox Test were used 
to evaluate survival data. Statistical analysis was performed using GraphPad 







Characterization of Staphylococcal Enterotoxin G and I 
SEG and SEI have been shown to cause robust T cell proliferation and with 
massive cytokine release in human T cell cultures [4, 5, 73 ]. Murine T cell 
responses vary in response to SE stimulation. HLA-DQ and C57BL/6 splenocytes 
were used to measure activity of SEG and SEI compared to classical 
superantigens, SEA and SEB using a standard 3 day thymidine incorporation 
assay Figure 2A. Splenocytes were isolated from 6-8 week old mice, stained with 
cell proliferation dye and stimulated with SEA, SEB, SEG, SEI (all 1µg/ml), 
using concanavalin A (1µg/ml and media alone as controls. As demonstrated 
previously, both CD4+ and CD8+ cells respond to SE stimulation and stimulated 
to a greater extent in HLA transgenic mice compared to C57BL/6 Figure 2B. 
These data confirm previous findings of enterotoxin potency and support using 
HLA transgenic mice to more accurately investigate the efficacy of SEG/SEI 
therapy.   
 
SE stimulation, including SEG and SEI, has been associated with increased levels 
of interferon gamma (IFNγ) both in vivo and in vitro. To identify which cells are 
responsible for this production, splenocytes were isolated and stimulated with 
SEG, SEI and SEG+SEI for 3 days. After which, cells were blocked with 
 23 
brefeldin A and monosen (BioLegend), permeabilized and stained for IFNγ 
Figure3. These data reveal CD8+ T cells from both C57BL/6 mice and HLA-
DQ8 mice produce IFNγ and CD4+ T cells from DQ8 mice produce more IFNγ 
than C57BL/6.  
 
Immune signals provoked by SE stimulation are often met with inhibitory 
immune signals that balance the immune response. PD-1 and CTLA-4, two such 
inhibitory molecules produced on T cells in response to activation, expression was 
evaluated on CD4+ and CD8+ T cells in response to SE stimulation (all 1µg/ml) 
Figure 4. CD4+ and CD8+ T cells were gated on CXCR3 expression, a chemokine 
receptor upregulated on activated Th1-like cells [126-130]. Collectively, these 
data support the potential for using immune checkpoint inhibitors, antibodies 
















































































Figure 2 . DQ8 mice respond strongly to staphylococcal enterotoxins G & I. 
Splenocytes isolated from 6-8 wk old DQ8 mice exhibited stronger mitogenicity to 
SEs (1ug/ml) compared to C57BL/6 mice in typical thymidine incorporation assay 
(A). Specific CD4+ and CD8+ T cell proliferation was measured by dye dilution via 
flow cytometry and reported as % proliferation (B). n=3-5. Graphed mean with SD. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.001.  
****


























































































































































































Figure 3. SEG and SEI elicit Type 1 effector CD4+ and CD8+ T cells.  
Splenocytes were stimulated for 3 days with indicated SE concentrations where 
CD4+ (A) and CD8+ (B) cells were evaluated for intracellular IFNy and Tbet 
production. Representative flow data of SEG+SEI (10ng/ml) (C). n=3-5. Graphed 




















































































































































Figure 4. Activated CD4+ and CD8+ T cells express PD-1 and CTLA-4.  
SEG and SEI (1ug/ml) demonstrate increased CXCR3 expression (A), along with PD-
1 (B) and CTLA4 (C) expression on DQ8 T cells . All cells were gated on 
Singlets>Live cells>cells>CD3. n=3-5. Graphed mean with SD. *p<0.5, **p<0.01, 
***p<0.001, ****p<0.001  







































Peritoneal Tumor Models  
Cells injected into the peritoneal cavity have been demonstrated to associate with 
specific locations within the cavity with several fat deposits have been extensively 
characterized in throughout the peritoneum. DQ8 mice were originally created 
using multiple strains of mice under the same MHC allotype, H2b. It is reasonable 
to hypothesis tumor models using cells originating from C57BL/6 mice, MHC 
allotype H2b, would implant in HLA mice. Mixed lymphocyte reactions using 
mitomycin C treated C57BL/6 splenocytes were cocultured with DQ8 splenocytes 
to measure proliferation Figure 5. These data do not indicate DQ8 T cells 
proliferate in response to mitomycin C or irradiated (data not shown) C57BL/6 
splenocytes. 
 
To this end, several tumor cell lines were investigated for potential use. Murine 
colon cancer cell line MC38 was implanted (2.5x105 cells IP) in various strains of 
6-8 week old male mice Figure 6. In general, HLA mice survived longer than 
allogeneic C57BL/6 mice; however, using tumors models with LD50 resolving at 
day 50 would be time consuming. The BALB/c derived mammary tumor cell line 
4T1, H2d allotype, was implanted IP in 6-8 week old female mice to confirm 























Figure 5 . DQ8 lymphocytes to not proliferate when cocultured with C57BL/6 
splenocytes. 
Mitomycin C Treated C57BL/6 Splenocytes (Stimulator Cells, red) were cocultured 
with DQ8 splenocytes (Responder Cells, blue) for 3 days. CD3+ T cell proliferation 
(green) was measured by dye dilution via flow cytometry and reported as % 
proliferation. SEB was used as a positive proliferative control.   
Stimulator Cells 
Proliferating 












Figure 6 . MC38 survival in HLA transgenic mice.  
2.5 x 105 live MC38 cells were implanted into the peritoneal cavity, suspended in 
100ul HBSS, of 6-8 week old male DQ8, DR3 and C57BL/6 mice. Kaplan Meier 
curves with Log-rank test shown.   








































Figure  7. 4T1 survival in HLA transgenic mice.  
2.5 x 105 live MC38 cells were implanted into the peritoneal cavity, suspended in 
100ul HBSS, of 6-8 week old female DQ8, DR3, BALB/c and C57BL/6 mice. 
Kaplan Meier curves with Log-rank test shown.   


















In this study, B16-F10 murine melanoma, a classic tumor model used widely used 
to elucidate antigen specific T cell responses, and Lewis lung carcinoma (LLC) 
cells, the premier model for NSCLC, were chosen. Cells, and treatment, were 
administered intraperitoneally making sure to wipe the needle with 70% alcohol 
to prevent subcutaneous implant. B16 cells were found to preferentially attach to 
the omental tissue with minimal seeding throughout the mesentery Figure 8. LLC 
cells also attach to omental tissue but appear to favor the mesentery later post 
implant.   
 
Omental tissue has long been identified as an important site for immune responses 
in the peritoneum. Several studies have characterized immune cells within the 
omentum  from lymphoid follicles, often referred to as milky spots (sorn). 
Therefore, C57BL/6 mice and HLA transgenic mouse omentum was evaluated 
using a similar technique outlined in [102]. In Figure 9, omental tissue was 
harvest, washed with HBSS and allowed to float in cDMEM for 2 days; after 
which cells were analyzed via flow cytometry.  These data compare previously 
reported T cell percentages in omental tissue [105] and show no differences in T 
cell composition among mice tested. However, CD4+ and CD8+ T cell populations 
























Figure 8 . B16-F10 cells establish at the omentum by day 6 post implant.  
2.5 x 105 live B16-F10 cells were implanted into the peritoneal cavity, suspended in 
100ul HBSS, of 6-8 week old female DQ8 and C57BL/6 mice. Images were taken 6 
days post implant with representative mouse shown. Undisturbed peritoneal cavity 





















Figure 9 . Omental T cell characterization.  
Omental tissue was placed in 1ml media and incubated for 2 days. Cells (including 
adherent cells collected w/trypsin dissociation) were analyzed after exclusion of 
doublets, debris and dead cells. T cells reported as % live cells (A) and % TCRβ+ 
(B). Graphed mean with SD. *p<0.5, **p<0.01, ***p<0.001, ****p<0.001 
















































SEG/SEI in Treatment of B16 Melanoma 
The therapeutic efficacy of enterotoxins was demonstrated previously by 
Kominsky et. al. [78] using SEA and SEB in a vaccine model for B16 melanoma 
in C57BL/6 mice. In this study, 60% of mice receiving 1x106 irradiated (15,000 
rads) 13 days before tumor challenge survived >140 days when boosted with 
SEA+SEB (25µg each) prior to tumor challenge. Unfortunately, these findings 
have been difficult to translate into human therapies due to neutralizing antibodies 
against them in patients with prior exposure. To that end, SEG and SEI were used 
following the same protocol in Kominsky et. al. Figure 10. Comparatively, SEG 
+ SEI provided minimal benefit in C57BL/6 mice when rechallenged (2.5x105 
cells) >60 days post initial implant 10B. Interestingly, ~10% of DQ8 10A mice 
responded well to B16 challenge when receiving just the irradiated cells alone 
compared to DR3 Figure 10C. Moreover, SEG/SEI boosted the vaccine response 
in DQ8 mice where 3/3 mice survived initial tumor challenge with either 1 single 
day -7, or 2 treatments before initial implant. Upon rechallenge, 1/6 mice died 
along with age matched naïve controls (data not shown). Not surprisingly, 
SEG/SEI did not provide appreciable benefit for C57BL/6 mice in the B16 
vaccine model. Additionally, these data support using DQ8 over C57BL/6 mice to 
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Figure 10. SEG and SEI promote long term survival in B16-F10 vaccinated DQ8 
mice. 
DQ8 (A), C57BL/6 (B) and DR3 (D) 6-8 week old female mice were injected with 
1x106 irradiated (15,000 rads) B16-F10 cells IP day -13 (C). Treated mice were 
injected with 50ug each SEG+SEI day -7 and -3. SEG/SEI(1x) groups received 
SEG+SEI on day -7 only; whereas SEG/SEI(2x) groups received both doses of 
SEG/SEI. DQ8 and C57BL/6 mice surviving >60 days were rechallenged with 
2.5x105 live B16-F10 cells intraperitoneally. Age matched controls died as expected 
(data not shown). Kaplan Meier curves with Log-rank test shown. n=3-10.  
   


















Vaccine strategies for various cancers using animal models provide useful 
information immunologically yet provide minimal translational benefit when 
applied clinically. The treatment of an established solid tumor is more clinically 
beneficial and was investigated using Figure 8 as an established B16 tumor in 
DQ8 mice Figure 11. Treatment of C57BL/6 established tumors did not provide 
meaning benefit  even when using a lower initial tumor implant, 10,000 cell IP 
Figure 11C. This representative experiment shows long term survival in ~80% of 
DQ8 mice rechallenged >200 days post initial cell implant.  Based on the results 
of vaccination experiments, it was hypothesized that irradiated cells could provide 
longer term benefit to prevent reoccurrence. In this experiment, using irradiated 
cells 4 days post implant did not provide apparent benefit with or without 
SEG/SEI.  Considering laboratory observations over these experiments, 2 
injections of SEG/SEI (50µg) were provided better overall therapeutic efficacy. 
That said, injections of SEG/SEI proved toxic in some C57BL/6 mice and nearly 
all DR3 mice. DR3 mice did not benefit from a single SEG/SEI in an established 
B16 model (data not shown); although, lower amounts of SEG/SEI could provide 
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Figure 11 . SEG and SEI promote long term survival in DQ8 mice with 
established B16-F10 tumors.  
Mice were implanted with 2.5x105 (A) or 1x104 (B) live B16-F10 cells 
intraperitoneally day 0 and followed the treatment protocols (C) and (D), 
respectively. Mice surviving >200 days were rechallenged with 2.5x105 live B16-F10 
cells intraperitoneally (A). Age matched controls died as previously demonstrated 
(data not shown). n=4-10. Kaplan Meier curves with Log-rank test shown.  
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Characterization of the SEG/SEI Anti-B16 Response 
Plasma cytokines Figure 12 and chemokines Figure 13 were measured ~24 hours 
after each SEG/SEI injection measured using BioLengend’s LEGENDplex™ 
using BD FACSymphony™ flow cytometer. Standard curves were evaluated for 
appropriate error considered appropriate for all parameters given. The data can be 
interpreted collectively and demonstrate a powerful IFNγ response in all mice 
tested and levels are not as elevated 24 hours after the second injection. This 
decreased level could be a result of inhibitory molecules on the T cells after SE 
stimulation, Figure 4; or the IFNγ response peaks before 24 hours after the 
second SEG/SEI injection.  Eluded to in earlier with B16 survival, DR3 mice 
demonstrate a toxic inflammatory response, a cytokine storm, demonstrated by 
increased TNFα, IL-6 and IL-10 after the second SEG/SEI injection. Numerous 
CC and CXC chemokines are increased in response to SEG/SEI, namely IFNγ 
associated chemokines. Again, taken collectively, chemokine responses can be 
grouped into Th1, Th2 and Treg response for example [124, 125]. DR3 mice 
mirror the inflammatory response seen in aforementioned cytokine levels; like 
CCL11, and evidence of regulatory type responses from CCL20 and IL-10. A 
recent review nicely summarizes the vast implications of chemokines in relation 
to cancer immunotherapies [125]. These data, when taken at face value, provide 
insight into the nature of the systemic immune response from SEG/SEI and 
clearly show increased IFNγ plasma concentrations regardless of MHC. Although 
these data prove SEG/SEI is toxic to DR3 mice, there is no clear difference in 















































































































































































Figure 12 . Plasma cytokine concentrations 24 hours post SEG/SEI in mice with 
established B16-F10 melanoma. 
All mice were implanted with 2.5x105 live B16-F10 cells intraperitoneally. Blood 
was collected from the submandibular vein in EDTA tubes 24 hours after each 
SEG/SEI administration . All plasma samples were frozen and run together using 
BioLegend’s LEGENDplex Mouse Th cytokine panel. All DR3 mice died 24 hours 
post second SE injection. n=4-5. 

















































































































































































































































































































































































Figure 13. Plasma chemokine concentrations 24 hours post SEG/SEI in mice 
with established B16-F10 melanoma. 
All mice were implanted with 2.5x105 live B16-F10 cells intraperitoneally. Blood 
was collected from the submandibular vein in EDTA tubes 24 hours after each 
SEG/SEI administration . All plasma samples were frozen and run together using 
BioLegend’s LEGENDplex Mouse Proinflammatory chemokine panel. All DR3 mice 
died 24 hours post second SE injection. n=4-5. 
  























The data presented insofar demonstrate SEG/SEI elicit robust IFNγ responses but 
do not delineate antitumor response between DQ8 and C57BL6 mice.  Cell 
specific differences in DQ8 and C57BL6 responses to B16 melanoma, including 
cell populations and effector molecules, were evaluated at different time points 
during treatment. In Figure 14, spleens and peritoneal lavage cells were collected 
13 days post implant and stained for surface CD3, CD4 and CD8 expression, 
including intracellular perforin and granzyme B in CD4 + A and CD8+ B T cells. 
Flow cytometry analysis reveals that DQ8 mice produce more CD8+ T cells that 
contain perforin and granzyme B in both the spleen and peritoneal cavity.  
 
CD3, CD4, CD25 and CD39 expression including intracellular FoxP3 was 
evaluated similarly to investigate T regulatory cell (Treg) responses Figure 14C. 
CD39 was selected, out of many, to investigate suppressive functionality of Tregs 
by Treg cells converting ATP to adenosine [134-137]. It stands to reason that 
inadequate T cell responses are responsible for poor survival in C57BL/6 mice, 












































































































































































Figure 14 . HLA-DQ8 CD8+ T cells produce perforin and granzyme B. 
Splenocytes and peritoneal lavage cells were evaluated 13 days post B16-F10 implant 
(2.5x105 cells IP) from DQ8 and C57BL/6 mice. Effector molecules perforin and 
granzyme B production in CD4+ (A) and CD8+ (B) T cells, along with T regulatory 
cells (C) via flow cytometry. . Groups presented were treated with 50ug each SEG & 


























































































In order to specifically determine which cells are functionality cytotoxic, CD4+ 
and CD8+ T cells were isolated from spleens 13 days post B16 implant from 
treated and non-treated mice, including naïve controls. Specific T cells were 
cocultured with B16-F10 melanoma cells for 4 hours in vivo at 50:1 
effector:target ratio Figure 15. Cytotoxicity was measured and reported as 
annexin V and propidium iodide double positive B16-F10 cells, gated to exclude 
T cells.  Unfortunately, these data did not show meaningful differences in 













































































































































































Figure 15. Day 13 splenocyte cytotoxicity against B16-F10.  
CD4+ (A) and CD8+ (Β) T cells isolated from splenocytes 13 days post B16-F10 
implant (2.5x105 cells IP) from mice treated with 50ug each SEG & SEI on day 6 and 
9 post implant, nontreated B16 alone and naïve controls. Cells were cocultured at a 
50:1 (T cell:B16) ratio for 4hrs in 96 well flat bottom plates. Representative flow 
cytometry plots of annexin V and PI staining (Gate: Singlets>B16-F10 cells) shown 
and reported as % annexin V+/PI+ B16-F10 cells. n=3. *p<0.05. 
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The presence of CD8+ T cells that contain perforin and granzyme 13 days post 
tumor implant suggest a potential cell mediated response in DQ8 mice not present 
in C57BL/6 compatriots. Expanding on day 13 observations, day 15 lymphoid 
tissue was evaluated for memory responses generated from SEG/SEI compared to 
naïve controls Figure 16.  B16 tumor alone groups for memory responses proved 
variable in results possibly due to the nature of the inherent immune response to 
B16. The B16 alone group was include for DQ8 mice for comparison. These data 
highlight the immune cell populations in the spleen, inguinal lymph nodes and the  
peritoneum. The percent CD3+ population between naïve C57BL/6 and DQ8 were 
no different in spleens and peritoneum Figure 16A and were increased day 15 
post implant in response to SEG/SEI treatment. Not unexpected, CD49b+ NK 
cells were similarly increased with SEG/SEI treatment including CD49b+TCRβ+ 
NKT cells. Further analysis finds the breakdown of CD4+/CD8+ populations differ 
between genotypes with DQ8 mice presenting lower CD4+/CD8+ ratios compared 
to C57BL/6 mice Figure 16B,C. Given that these mice have similar numbers of 
























































































































































































































































Figure 16. CD8+ T cells are increased in SEG/SEI treated HLA-DQ8 mice.  
DQ8 and C57BL/6 splenocytes, peritoneal lavage cells, and inguinal lymph nodes 
were evaluated 15 days post B16-F10 implant (2.5x105 cells IP) from SEG/SEI 
treated and naïve mice.  (A) CD3+ cells were increased in SEG/SEI treated groups, 
whereas CD49b+ (NK) cells were decreased. (B,C) CD4+ and CD8+ T cells are 
reported as % live cells. Groups presented were treated with 50ug each SEG & SEI 
on day 6 and 9 post implant. n=3-5. Graphed mean with SD. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.001.  
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As mentioned previously, the durability of T cell therapies providing lasting 
immunity is limited. In that light, memory T cell populations were characterized 
using anti-CD44, -CD62L, -CD3, CD4, CD8 and KLRG1 and analyzed via flow 
cytometry Figure 17. Including KLRG1 was used to differentiate between 
effector and memory cells with effector cells expressing higher levels upon 
activation and decreased levels in memory cells [142-145]. Take together data 
provide a glimpse into the trafficking of immune cells in response to SEG/SEI. It 
would be easy to focus on the effector, CD44+CD62L- , populations, but the 
differences in naïve mice complicate the interpretation of these data. Of note, 
CD8+CD44+CD62L+KLRG1- cells are increased in the inguinal lymph nodes and 
spleens of DQ8 mice compared to controls Figure 17 B,F. Differences could be a 
result of a delayed response in C57BL/6. CD8+CD44+CD62L+ cells in the 
peritoneum of C57BL/6 are increased compared to DQ8 mice. Taking into 
consideration day 13 and 15 responses these data suggest SEG/SEI elicit a 
powerful, lasting CD8 response against B16 melanoma unseen in identically 











































































































































































































































































































































































































































































































































Figure 17. CD44+CD62L+KLRG1-CD8+ T memory cells are increased in 
SEG/SEI treated HLA-DQ8 mice.  
DQ8 and C57BL/6 splenocytes, peritoneal lavage cells, and inguinal lymph nodes 
were evaluated 15 days post B16-F10 implant (2.5x105 cells IP) from SEG/SEI 
treated and naïve mice. Representative scatter plots of cells from mice treated day 6 
and 9 post implant with SEG/SEI (A-C). CD44 and CD62L expression (D,F) along 
with KLRG1 (E,G) was used to characterized effector and memory CD4/CD8 T cells 
were gated to exclude doublets, debris and dead cells from analysis. n=3-5. Graphed 



































































































































































































































































Figure 18 . Day 15 peritoneal lavage cell cytotoxicity against B16-F10.  
CD4+ (A) and CD8+ (Β) T cells isolated from peritoneal lavages of SEG/SEI treated 
and non-treated mice 15 days post implant. Cells were cocultured at a 10:1 (T 
cell:B16) ratio for 4hrs in 96 well flat bottom plates. Representative flow cytometry 
plots of annexin V and PI staining (Gate: Singlets>B16-F10 cells) shown and 
reported as % annexin V+/PI+ B16-F10 cells. n=5. *p<0.05. 
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SEG/SEI in Treatment of Lewis Lung Carcinoma  
Pushing the success demonstrated by introducing SEG/SEI in the treatment of 
melanoma, LLC cells were used to evaluate a tumor with a different immune 
contexture. LLC cells were deployed similar to the peritoneal model used to 
assess SEG/SEI against B16 melanoma Figure 19.  Survival of mice with B16 or 
LLC were similar albeit 250,000 LLC cells at implant prove more lethal in DQ8 
mice compared to 10,000 cells at implant Figure 20.  
 
SEG/SEI therapy proved ineffective in treating an established LLC tumor using 
the same treatment protocol which demonstrated robust anti-B16 responses 
Figure 21. It would be reasonable to think that lowering the tumor burden to 
10,000 cells at implant would provide some benefit. Nope Figure 22. Irradiated 
LLC cells were used to provide antigen for an antitumor response which would in 
turn be enhanced with SEG/SEI. This provided no benefit to the mice. The only 
hypothesis supported throughout these experiments is that LLC tumors have a 















Figure 19. Lewis lung carcinoma implanted intraperitoneally is more lethal in 
HLA-DQ8 mice compared to allogeneic C57BL/6. 
Syngeneic C57BL/6 6-8 w.o. female mice were implanted with 2.5x105 live LLC 
cells IP along with DQ8 and DR3 mice. Kaplan Meier survival curves shown with 
Log-rank test corrected for multiple comparisons. n=6-14. *p=0.05, **p=0.01, 
***p=0.001. 
 





























Figure 20. Mice implanted intraperitoneally with 10,000 LLC cells. 
6-8 w.o. male mice were implanted with 1x104 live LLC cells IP. Kaplan Meier 
survival curves shown. n=10.  
 


































Figure 21. SEG/SEI does not elicit antitumor responses in DQ8 mice with an 
established LLC tumor.  
DQ8 6-8 w.o. female mice were implanted with 2.5x105 live LLC cells IP. Treated 
mice received 50µg SEG and 50µg SEI IP day 6 and 9 post implant. Kaplan Meier 
survival curves shown. n=10.  
 


















Treatment post implant 


































Figure 22. Initial LLC implant dosage does not affect SEG/SEI treatment 
outcome. 
DQ8 mice implanted with 1x104 live LLC cells received 1x106 irradiated (15,000 
rads) LLC cells, 50µg each SEG/SEI, both, or no treatment. Kaplan Meier survival 
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There have been several immunotherapies recently approved that are used to 
augment the immune response. In fact, inflammation was critical and deemed 
necessary in Coley’s descriptions of his treatments provoking erysipelas [63-66]. 
To that end, toll like receptor (TLR) agonists were included in the treatment 
protocol of LLC Figure 23. These data show a deleterious effect when used 
synergistically with SEG/SEI. This could simply be corrected with dosage 
titrations, but this researcher hypothesizes the use of TLR agonists will not 
favorably shape the immune environment of the LLC tumor.  
 
Recently, several antibodies have been evaluated and approved that target 
inhibitory molecules, like PD-1 and PD-L1 on the T and LLC cells, respectively 
[150-156]. SE stimulation has been shown to increase inhibitory signals on T cells 
Figure 4. Therefore, anti-PD1 and anti-PDL1 were incorporated into the 
treatment protocol for LLC tumors Figure 24. Anti-PDL1 therapy was given 6 
and 10 days post implant and conferred enhanced survival in DQ8 mice when 
given without SEG/SEI Figure 24A.  Utilizing anti-PD-1 did prolong survival in 
DQ8 mice similar to using anti-PDL1. DQ8 mice receiving anti-PD-1 along with 
SEG/SEI on days 4 and 8 post implant increased survival in 10% of mice but did 
not protect upon rechallenge with LLC. The collection of LLC results using 
various immunotherapeutic tools again supports a highly inflammatory LLC 
tumor environment in the peritoneum of DQ8 mice. Although beneficial in B16 
melanoma, the immune contexture of LLC tumors will require further 











Figure 23. TLR agonists exacerbate SEG/SEI therapy. 
6-8 w.o. female mice were implanted with 2.5x105 live LLC cells IP. 20µg LPS 
(Sigma L6143) or 40µg YscF (Alvine) were combined with 50µg each SEG/SEI 
(France) just before injecting IP day 6. Treatment mice received 50µg each SEG/SEI 
day 9. . Kaplan Meier survival curves shown with Log-rank test. n=3/experimental, 
6/controls. *p=0.05, **p=0.01, ***p=0.001 






























































































Figure 24. Including anti-PD-1 and anti-PD-L1 therapy to established LLC 
treatment protocol prolongs survival in DQ8 mice.   
DQ8 mice implanted with 2.5x105 live LLC cells received 50µg each SEG/SEI with 
200µg anti-PD-L1 (A) or anti-PD-1 (B) at days indicated. Mice were rechallenged 
with 2.5x105 live LLC cells and subsequently died with controls (data not shown). All 
injections done IP in <200µl total volume in 6-8 w.o. female mice. Kaplan Meier 
survival curves shown with Log-rank test corrected for multiple comparisons. n=6. 
*p=0.05, **p=0.01, ***p=0.001. 
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It is necessary to take into consideration the history into current understanding of 
the immune system and the factors that can influence the interpretation of the data 
collected from studies in vitro or vivo. Mouse models have advanced to support 
grafting human cells creating humanized mice to study cancer. The experiments 
shown here use HLA transgenic mice that express a single cell surface receptor 
from the human immune system, DQ8. HLA transgenic mice do allow for some 
meaningful data into the role of receptor based specificity that can drive an 
autoimmune response. Autoimmune responses are characterized as an 
inappropriate reaction against host, self-antigen. Experiments that aim to elucidate 
a similar relationship in cancer have been underway for years. The search for 
tumor associated antigens (TAAs) peaked in the 1990s and has recently evolved 
into the search for neoantigens pioneered by Dr. Stephen Rosenberg [60]. 
Recently, another therapy using SEG/SEI could be poised to attack tumors 
through another cellular therapy, sickle cells. These cells have the capacity to 
stick in the tumor vasculature, rupture, and release cytotoxic compounds directly 
at the tumor site [158, 159].  
 
Long term, progression free survival was achieved in many animals throughout 
this study. HLA-DQ8 mice are able to respond favorably to 50 µg doses of SEG 
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and SEI and these responses can be directed towards an established B16-F10 
tumor and can provide memory responses in rechallenged mice. However, these 
tumors responses are specific. The treatment of an established LLC tumor proved 
difficult in all strains of mice used. Interestingly, anti-PD1 and -PD-L1 therapy 
did prolong survival when tested in HLA-DQ8 mice. Studies were not done in 
C57BL/6 mice due to the lack of SE response in B16-F10 models. Experiments 
using different concentrations of LLCs at implant yielded varying results and 
where used to compare B16-F10 implant load. LLC models could use a lower 
number of cells at implant as the survival of 10,000 cells vs 250,000 cells is 
negligible; however, 10,000 B16-F10 cells can lead to variable tumor outgrowth. 
SEG/SEI activated a subset of T cells and skewed the immune contexture towards 
T cells expressing Tbet, IFNy, perforin, and granzymes b at day 13 post 
treatment. Rechallenge studies >200 days post implant yielded 100% survival >70 
days post rechallenge. The data presented throughout this document provide 
evidence to support investigation into incorporating SEG and SEI into current 
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